SageView Advisory Group’s Biogen BIIB Stock Holding History

SageView Advisory Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$273K	Sell	1,263 -2	-0.2%	-$383	0.01%	522
2026 Q1	$232K	Buy	1,265 +12	+1%	+$2.21K	0.01%	540
2025 Q4	$221K	Buy	+1,253	New	+$205K	0.01%	566
2024 Q1	–	Sell	-951	Closed	-$235K	–	536
2023 Q4	$235K	Buy	951 +72	+8%	+$17.7K	0.01%	582
2023 Q3	$226K	Buy	879 +72	+9%	+$19.3K	0.01%	489
2023 Q2	$230K	Buy	807 +54	+7%	+$16.1K	0.01%	502
2023 Q1	$209K	Buy	753 +11	+1%	+$3.04K	0.01%	445
2022 Q4	$205K	Buy	+742	New	+$210K	0.02%	394

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SageView Advisory Group's BIIB Position: Q2 2026 in Review

SageView Advisory Group reduced its Biogen (BIIB) stake by 0.16% in Q2 2026, selling an estimated $383 and leaving 1,263 shares worth $273K. The position accounts for 0.01% of the portfolio, ranked #522.

SageView Advisory Group first reported a position in BIIB in Q4 2022 and has held it in 8 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

SageView Advisory Group held 1,263 shares of Biogen worth $273K as of Q2 2026.
SageView Advisory Group sold 2 Biogen shares in Q2 2026, an estimated $383.
Biogen made up 0.01% of SageView Advisory Group's portfolio in Q2 2026, its #522 holding.
SageView Advisory Group first reported a position in Biogen in Q4 2022 and has held it in 8 quarters since.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on SageView Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.